Dr. Mateusz Dasko, Marie Sklodowska-Curie IF researcher at the University, has presented the most recent results of the use of folic acid to
transport biologically active compounds in Nice. This strategy is crucial to
improve the pharmacokinetic and physicochemical properties of active compounds
that do not comply with Lipinski's 'rule of 5', such as the PROTACs that
Mateusz is developing in the current MSCA-IF project. In this year, Dr. Mateusz Dasko has started the
Marie Sklodowska-Curie Individual Fellowship at the Faculty of Pharmacy. Together
with Prof. Beatriz de Pascual-Teresa and Dr. Irene OrtÍn Rem?n, he participates
in the project entitled "Design, synthesis and biological evaluation of
PROteolysis-Targeting Chimeric (PROTAC) molecules as anticancer agents, PROTACs
- Project ID: 101031883", which focuses on the development of drugs
with antitumor activity by selective protein degradation.
Early this September, Nice (France) was a host city of XXVII
International Symposium on Medicinal Chemistry (ISMC) organized
by the European Federation for Medicinal Chemistry (EFMC), which is the
main European organization for the Medicinal Chemistry and Chemical Biology
areas. The EFMC is an independent association that represents 29 scientific
organizations from 25 European countries with more than 9000 scientists. The
biennial EFMC-ISMC is a key symposium in the Medicinal Chemistry field, and it
traditionally attracts around 10000 participants, (from industry and academia. The
programme of XXVII EFMC ISMC covered advances in drug discovery in major
therapeutic areas, including bacterial and viral infections,
neurodegenerative and cardiovascular diseases, rare diseases, and cancer.